The Therapeutic Potential of Essential Oils in Managing Inflammatory Skin Conditions: A Scoping Review
Abstract
:1. Introduction
1.1. Essential Oils and Aim of this Scoping Review
1.2. Inflammatory Skin Conditions
2. Results
2.1. Scoping Review
2.2. Acne
Author(s) (Publication Year; Country) | Study Design (n) | Intervention (n) | Control (n) | Outcome Measure(s) | Study Duration (Evaluation Period) | Main Results | Limitations |
---|---|---|---|---|---|---|---|
Enshaieh et al. (2007; Iran) [36] | Randomized, double-blind, and placebo-controlled study (60) | 5% TTO 1 in carbomer gel (30) | Carbomer gel (30) | —Total lesion count —ASI 2 —Number of comedones, papules, and pustules —Monitoring ADRs 3 | 45 days (baseline and every 15-day period) | —After treatment, a significant reduction in the mean TLC 4, ASI 2, and the numbers of comedones, pustules, and papules in the intervention group was observed but not in the control group (significant difference) —5 patients reported minimal pruritus, 3 patients reported a little burning sensation, and 1 patient reported minimal scaling (divided over the intervention and placebo groups) | —Short duration of study and follow-up time —Small sample size |
Kwon et al. (2014; South Korea) [37] | Prospective double-blind, randomized, and controlled split-face trial (34) | 5% Lactobacillus-fermented Chamaecyparis obtusa (LFCO) in cream (34) | 5% TTO 1 in cream (34) | —Acne grade —(Non-)Inflammatory lesion count —Histopathology and immunohistochemistry of lesions —Patients’ subjective assessment —Average size of sebaceous glands —Sebum secretion —Monitoring ADRs 3 | 8 weeks (baseline; 1, 2, 4, and 8 weeks) | —A significant difference between both groups in inflammatory lesion counts and acne grading was observed after 2 weeks and for non-inflammatory lesion counts after 4 weeks —A significant reduction in the overall size of the sebaceous gland was observed on the lactobacillus side when compared to the baseline, but not on the tea tree oil side —In the tea tree oil group, 4 patients reported mild dryness and 6 reported mild erythema and desquamation —In the lactobacillus group, 2 patients reported mild dryness and 2 reported dryness | —Risk of cross-contamination —Lack of comparison to a control or placebo —Small sample size and all were Korean |
Da Silva et al. (2012; Brazil) [38] | Double-blind and placebo-controlled clinical trial (10) | 1% Copaiba essential oil in natrozol gel (10) | Natrozol gel (10) | —Photographs to determine the total area occupied by acne | 21 days (baseline and weekly) | —After 21 days, a highly significant decrease in the extent of the area affected by acne was observed in both the placebo and intervention groups; however, the effect in the intervention group was greater —The results observed in the placebo group could not be explained, and aggravations occurred in most of the participants —The decrease in the surface area affected with acne in the intervention group can mostly be explained by the model | —Short duration of study and follow-up time —Small sample size —Only one outcome —No safety assessment —No demographics reported |
Bassett et al. (1990; Australia) [39] | Prospective and single-blind comparative study (124) | 5% TTO 1 in gel (61) | 5% benzoyl peroxide in lotion (63) | —Severity of acne (counting technique) —(Non-)Inflammatory lesion count —Oiliness, erythema, scaling, pruritus, and dryness —Monitoring ADRs 3 | 3 months (baseline and three times with monthly intervals) | —At the baseline, a greater facial erythema assessment was observed in the tea tree oil group compared to the benzoyl peroxide group —At 1, 2, and 3 months, benzoyl peroxide reduced a greater number of inflamed lesions compared to the tea tree oil group; however, the reduction in both groups was significant —There was not a significant reduction in non-inflamed lesions observed in both groups —79% of the benzoyl peroxide group reported ADRs 3, whereas 44% of the tea tree oil group reported ADRs 3 (a significant difference) | —Lack of control or placebo group |
Ghovvati et al. (2019; Iran) [40] | Open-label, assessor-blind, and uncontrolled clinical trial (20) | 0.5% cinnamon in gel (20) | NA | —(Non-)Inflammatory lesion count —Size and quantity of follicular fluorescence spots —Skin biophysical parameters —Monitoring ADRs 3 | 45 days (baseline; 4 and 8 weeks) | —ADRs to 1% cinnamon in gel were observed in 6 subjects; therefore, the 0.5% cinnamon in gel was used in this trial —After 8 weeks, significant reductions in the non-inflammatory and inflammatory lesion counts, sebum content, and erythema index were observed compared to the baseline —Non-significant changes were observed for the skin hydration and melanin index —13 patients reported mild burning and 11 patients reported facial redness after using the cinnamon gel | —Lack of comparison to a control, placebo, or standard therapy —Short duration of study and follow-up time —Small sample size —No demographics reported |
Talebi et al. (2020; Iran) [41] | Open-label, assessor-blind, and uncontrolled clinical trial (20) | 1% (w/w) ajwain in gel (20) | NA | —Digital and fluorescence photography —Biophysical skin profile measurement (stratum corneum hydration, sebum content, TEWL 5, erythema index, melanin, and pH value) —TLC 4 —VAS 6 —Monitoring ADRs 3 | 8 weeks (baseline; 4 and 8 weeks) | —After 8 weeks, a significant reduction in the total lesion count, non-inflammatory lesion count, and a mean decrease in the size and quantity of red spots was observed —After 8 weeks, the decreases in sebum and pH values were significant —No ADRs 3 were reported | —Lack of comparison to a control, placebo or standard therapy —Small sample size |
Malhi et al. (2017; Australia) [42] | Uncontrolled, dual-center, and open-label phase II pilot study (14) | 200 mg/g of TTO 1 gel and 7 mg/g of tea tree face wash (14) | NA | —IGA 7 score —TLC 4 —Skin oiliness —Frequency of ADRs 3 —Mean local tolerability score | 12 weeks (baseline; 4, 8, and 12 weeks) | —After 4, 8, and 12 weeks, a significant reduction in the TLC 4, IGA 7 score, and facial oiliness score was observed —Adherence was high, and no serious adverse events were reported | —Lack of comparison to a control, placebo, or standard therapy —Short duration of study and follow-up time —Small sample size |
Hassan et al. (2013; Saudi Arabia) [43] | Clinical trial (5) | Eucalyptus oil in cream (5) | NA | —Photographs —Outcomes not defined | 10 days (monitored routinely) | —All patients showed good results after the second week of treatment | —Lack of comparison to a control, placebo, or standard therapy —Short duration of study and follow-up time —Small sample size —No specific outcomes reported —No safety assessment |
Najafi-Taher et al. (2022; Iran) [44] | Triple-blind and randomized clinical trial (100) | TTO 1 nano-emulsion in adapalene gel (53) | Adapalene gel (47) | —Number of (non-)inflammatory lesions —TLC 4 —ASI 2 —Monitoring ADRs 3 | 12 weeks (baseline; 4, 8, and 12 weeks) | —Number of (non-)inflammatory lesions, TLC 4, and ASI 2 showed a greater improvement in the intervention group compared to the positive control —Only mild ADRs 3 were reported in both groups, with dryness being the most common adverse effect | —Lack of comparison to a control or placebo |
Mazzarello et al. (2018; Italy) [46] | Single-center, randomized, and double-blind comparative study (60) | —Group A: 20% propolis, 3% TTO 1, and 10% Aloe vera (PTAC) in cream (20) | —Group B: erythromycin cream (20; positive control) —Group C: vehicle (20; placebo) | —Cutaneous status —Macro-photography —Quantity of sebum —Skin surface pH —Cutaneous erythema index —Number of comedones, papules, and pustules —TLC 4 —ASI 2 | 30 days (baseline; 15 and 30 days) | —All the clinical and instrumental values studied were statistically different from the placebo group —The sebometry, pH, and erythema index values were not significantly different statistically during the treatment in the three study groups —The intervention of group A was more effective in reducing ASI 2 and TLC 4 compared to the intervention of group B —The interventions of both groups A and B showed a significant reduction in the number of (non-)inflammatory lesions | —Short duration of study and follow-up time —No safety assessment |
Mazzarello et al. (2020; Italy) [47] | Comparative randomized, single-center, and single-blind study (60) | 3.74% Myrtus communis L. essential oil, 0.1% Origanum vulgare essential oil, and 0.025% tretinoin (MOTC) in cream (30) | 1% clindamycin and 0.025% tretinoin (CTG) (30; cream) | —Amount of skin sebum, pH, erythema index, and TEWL 5 —Macro-photography —Number of comedones, papules, and pustules —TLC 4 —ASI 2 | 30 days (baseline; 15 and 30 days) | —All the instrumental values studied were statistically different between the two groups; however, no sebometry and pH changes were observed in both groups —The MOTC intervention was better than the CTG control in reducing the popular erythema index —In the CTG control group, erythema of the inter-papular healthy skin significantly increases statistically —Both products improved clinical parameters, and no statistically significant differences were detected between the groups | —Lack of comparison to a placebo —Short duration of study and follow-up time —No safety assessment |
Parveen et al. (2009; India) [48] | Controlled, randomized, and single-blind clinical trial (30) | Unani herbomineral in cream (20) | Vehicle of cream (10) | —IGA 7 | 60 days (baseline; 15, 30, 45, and 60 days) | —The IGA 7 means show a very significant difference between the baseline and day 15, day 30, day 40, and day 60 after treatment, whereas very significant differences in the placebo group were observed between the baseline and days 45 and 60 —No significant difference in the IGA 7 was observed between the baseline and days 15 and 30 in the placebo group | —Lack of comparison to a standard therapy —No safety assessment —Low number of outcomes |
Kim and Shin (2013; South Korea) [49] | Non-equivalent control group, pretest–post-test design (54) | A basic, weekly acne treatment and a dermal application of a mixture of 3% TTO 1 and 2% lavender oil in jojoba oil as the carrier (27) | Basic, weekly acne treatment (27) | —Acne-related characteristics —Number of P. acnes —Number of human skin pathogens —Number of acne lesions —Sebum secretion rates | 4 weeks (baseline and weekly) | —A significant reduction in the total number of P. acnes, the sebum excretion rate, and non-inflammatory skin lesions was observed in the intervention group but not in the control group —The number of human skin pathogens showed no significant difference in both groups —The number of acne lesions was significantly reduced in both groups | —Short duration of study and follow-up time —Small sample size —No safety assessment |
Orafidiya et al. (2002; Nigeria) [50] | Preliminary clinical tests (126; seven subjects per product) | Ocimum gratissimum leaf essential oil preparations (1% v/v polysorbate 80, cetomacrogol blend, and petrolatum base, or 50% v/v alcohol) (112) | —Reference: 10% benzoyl peroxide in lotion (7) —Placebo: 40% arachis oil in 1% v/v polysorbate 80 (7) | —Number of comedones, papules, and pustules (acne lesion count) —Number of days taken to achieve a 50% reduction in lesion count —Skin sensitivity —Patient acceptability —Monitoring ADRs 3 | 4 weeks (baseline and weekly) | —The intervention products were significantly more effective in reducing lesions than the placebo —The effect of the reference treatment was gradual over the 9 days, being more pronounced in the later part of the treatment period —A burning sensation was the most reported adverse event within the intervention group —In the placebo group no adverse events were reported | —Short duration of study and follow-up time —Small sample size in the different treatment groups —No demographics reported |
Orafidiya et al. (2004; Nigeria) [51] | Preliminary clinical investigation (84; 12 subjects per product) | Ocimum gratissimum leaf essential oil preparations (lotion in 25% and 50% of aqueous aloe gel or 100% of aloe gel) (48) | —Reference/positive control: 1% clindamycin solution (12) —Negative control: Neat aloe gel dispersed in 1% polysorbate 80 (12) —Placebo: 40% of arachis oil emulsion in 1% v/v polysorbate 80 (12) | —Number of comedones, papules, and pustules (acne lesion count) —Number of days taken to achieve a 50% reduction in lesion count —Skin sensitivity -—Patient acceptability —Monitoring ADRs 3 | 4 weeks (baseline and weekly) | —In the negative control group, minimal activity was observed —A greater reduction in the substant lesion counts was observed in the intervention group compared to the negative and positive control groups —The preparations containing a greater quantity of aloe vera showed greater improved outcomes —Stinging sensation on the skin was the most reported adverse event (96%), which was tolerable —Only mild skin irritation was reported within the intervention group | —Short duration of study and follow-up time —Small sample size in the different treatment groups —No demographics reported |
Hassoun et al. (2016; United States) [52] | Case study (1) | Cedarwood oil tretinoin cream (1) | NA | NA | 4 weeks (baseline and 4 weeks) | —After 4 weeks of treatment, the patients’ faces were clear and had rare open and closed comedones on the chest with no papules | —Lack of comparison to a control, placebo, or standard therapy —Combination preparation —Only one case —Retrospective study —Uncontrolled |
Author(s) (Publication Year; Country) | Intervention (Origin) | Intervention: Self-Made or Purchased | Control | Control: Self-Made or Purchased | Analyses of the EO-Containing Product |
---|---|---|---|---|---|
Enshaieh et al. (2007; Iran) [36] | 5% TTO 1 gel (Melaleuca alternifolia) | Purchased from Cinere Company | Carbomer gel | Purchased from Cinere Company | The component levels were established through gas chromatographic analysis in accordance with the international standard |
Kwon et al. (2014; South Korea) [37] | 5% Lactobacillus-fermented Chamaecyparis obtusa (LFCO) cream (fermentation of C. obtusa by Lactobacillus fermentum) | Manufactured and provided by BST Corporation | 5% TTO in cream | Manufactured and provided by BST Corporation | —Bacterial strains and MIC 2 determination —RT-PCR 3 —Ultra-performance liquid chromatography and high-resolution mass spectrometry analysis |
Da Silva et al. (2012; Brazil) [38] | 1% copaiba essential oil (Copaifera langsdorfii) in natrozol gel | Self-extracted and self-made | Natrozol gel | Purchased | —Density and phytochemical profile —High-resolution gas chromatography analysis for identification of the EO 4 components |
Bassett et al. (1990; Australia) [39] | 5% TTO 1 gel (Melaleuca alternifolia tree) | Purchased | 5% benzoyl peroxide lotion | Purchased | Not conducted |
Ghovvati et al. (2019; Iran) [40] | 0.5% cinnamon gel (Cinnamomum verum bark oil) | Self-conducted extraction and preparation of topical gel | NA | NA | —Evaluation of color, odor, consistency, homogeneity, pH, density, and viscosity —Chemical quantification of the formulation |
Talebi et al. (2020; Iran) [41] | 1% (w/w) ajwain gel (Trachyspermum ammi (ajwain fruits) | Self-extracted and self-made | NA | NA | —Physicochemical evaluation: stability and viscosity —Gas chromatography analysis for identification of the EO 4 components |
Malhi et al. (2017; Australia) [42] | 200 mg/g TTO 1 gel and 7 mg/g tea tree face wash (Melaleuca alternifolia) | Purchased from Thursday Plantation | NA | NA | —Visual in vitro evaluation of MIC 2 after 48 h of anaerobic incubation (repeated thrice) |
Hassan et al. (2013; Saudi Arabia) [43] | Eucalyptus oil (Eucalyptus amaldulensis) in cream | Self-mixed all the purchased constituents | NA | NA | Not conducted |
Najafi-Taher et al. (2022; Iran) [44] | TTO 1 nano-emulsion (Melaleuca alternifolia) containing adapalene gel | Self-made adapalene-loaded TTO 1 nano-emulsion | Adapalene gel | Purchased from Aburaihan pharmaceutical Co. | —Characterization of nano-emulsion: DLS 5 and zeta potential analysis, TEM 6, viscosity, pH, and stability —In vitro: antimicrobial activity —Ex vivo: drug permeation and skin distribution —In vivo: skin irritation, systemic absorption, biochemical parameters, and histopathological analysis |
Mazzarello et al. (2018; Italy) [46] | —Group A: 20% propolis, 3% TTO 1, and 10% Aloe vera (enzymatic hydrolysis of the original plant glycosides, Melaleuca alternifolia and Aloe vera) | Purchased | —Group B: erythromycin cream (positive control) —Group C: vehicle (placebo) | Purchased by Humana Pharma International Spa | Not conducted |
Mazzarello et al. (2020; Italy) [47] | 3.74% Myrtus communis oil, 0.1% Origanum vulgare oil, and 0.025% tretinoin (MOTC) | Self-made | 1% clindamycin and 0.025% tretinoin (CTG) | Purchased | —Stability —pH —PET 7 (challenge test) —Susceptible test to different antibiotics |
Parveen et al. (2009; India) [48] | Unani herbomineral cream | Self-made | Vehicle cream | Not mentioned | Not conducted |
Kim and Shin (2013; South Korea) [49] | A basic, weekly acne treatment and a dermal application of a mixture of 3% TTO 1, 2%lavender oil, and jojoba oil | Unknown (the EOs are permitted by the Korean Food & Drug Administration) | Basic, weekly acne treatment. | Unknown (the acne intervention program was created through collaboration with a dermatologist, a member of the family practice faculty, and an aromatherapist) | Not conducted |
Orafidiya et al. (2002; Nigeria) [50] | Ocimum gratissimum leaf EO preparations | Purchased | —Reference/positive control: 1% benzoyl peroxide solution | Purchased | Not conducted |
Orafidiya et al. (2004; Nigeria) [51] | Ocimum gratissimum leaf EO preparations | Purchased | —Reference/positive control: 1% clindamycin solution | Purchased | Not conducted |
Hassoun et al. (2016; United States) [52] | Cedarwood oil (from Juniperus virginiana) mixed with tretinoin cream | Cedarwood oil was purchased and self-added to the tretinoin cream by the patient | Not conducted | NA | NA |
2.3. Dermatitis and Eczema
2.4. Psoriasis
2.5. Rosacea
3. Discussion
3.1. General Aspects
3.2. Tea Tree Oil (TTO)
3.3. Placebo-Controlled Clinical Studies
3.4. Clinical Studies without Comparison to a Control, Placebo, or Standard Therapy
3.5. Clinical Studies with Comparison to Standard Therapy
3.6. Clinical Studies with Comparison to a Placebo, Positive Control, and Negative Control
3.7. Reported ADRs
3.8. The Quality of the EO Products
3.9. Limitations of the Clinical Studies
3.10. Strengths and Limitations of this Scoping Review
3.11. Future Perspectives
4. Materials and Methods
4.1. Search Strategy
4.2. Study Selection
- Clinical studies, case studies, and randomized controlled studies making use of a product containing an EO or multiple EOs to treat acne, dermatitis and eczema, psoriasis, and/or rosacea.
- Reported efficacy and safety outcomes after the use of the intervention, control, and/or placebo.
- The studies were conducted with in vitro or in vivo models only.
- The article was a review or clinical trial protocol.
- The article’s full text was not available.
- Articles that reported an inflammatory skin condition caused by the use of a product containing an EO.
- Articles that made use of fixed plant-derived oils (triacyl glycerides) only.
4.3. Data Extraction
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Malik, S. Essential Oil Research: Trends in Biosynthesis, Analytics, Industrial Applications and Biotechnological Production; Springer: Cham, Switzerland, 2019. [Google Scholar]
- Manion, C.R.; Widder, R.M. Essentials of essential oils. Am. J. Health-Syst. Pharm. 2017, 74, e153–e162. [Google Scholar] [CrossRef] [PubMed]
- Price, S.P.; Price, L.; Price, P. Aromatherapy for Health Professionals, 5th ed.; Elsevier Limited: Amsterdam, The Netherlands, 2021. [Google Scholar]
- Koyama, S.; Heinbockel, T. The effects of essential oils and terpenes in relation to their routes of intake and application. Int. J. Mol. Sci. 2020, 21, 1558. [Google Scholar] [CrossRef] [PubMed]
- Başer, K.H.C.; Buchbauer, G. Handbook of Essential Oils: Science, Technology, and Applications, 3rd ed; CRC Press/Taylor & Francis: Boca Raton, FL, USA, 2020. [Google Scholar]
- Heinrich, M.B.; Rieto-Garcia, J.; Gibbons, S.; Williamson, E.M. Fundamentals of Pharmacognosy and Phytotherapy, 4th ed.; Elsevier Limited: Amsterdam, The Netherlands, 2023. [Google Scholar]
- Rhind, J.P. Essential Oils. A Comprehensive Handbook for Aromatic Therapy, 3rd ed.; Singing Dragon: London, UK; Philadelphia, PA, USA, 2020. [Google Scholar]
- Tisserand, R.; Young, R. Essential Oil Safety, 2nd ed.; Churchill Livingstone: Edingburgh, UK, 2014. [Google Scholar]
- Başer, K.H.C.; Demirci, F. Chemistry of essential oils. Chapter 4. In Flavours and Fragrances; Berger, R.G., Ed.; Springer: Berlin/Heidelberg, Germany, 2007; pp. 43–86. [Google Scholar] [CrossRef]
- De Sousa, D.P.; Damasceno, R.O.S.; Amorati, R.; Elshabrawy, H.A.; De Castro, R.D.; Bezerra, D.P.; Nunes, V.R.V.; Gomes, R.C.; Lima, T.C. Essential oils: Chemistry and pharmacological activities. Biomolecules 2023, 13, 1144. [Google Scholar] [CrossRef] [PubMed]
- Orchard, A.; Sandasi, M.; Kamatou, G.; Viljoen, A.; Van Vuuren, S. The in vitro antimicrobial activity and chemometric modelling of 59 commercial essential oils against pathogens of dermatological relevance. Chem. Biodivers. 2017, 14, e16218. [Google Scholar] [CrossRef] [PubMed]
- Bungau, A.F.; Radu, A.F.; Bungau, S.G.; Vesa, C.M.; Tit, D.M.; Purza, A.L.; Endres, L.M. Emerging insights into the applicability of essential oils in the management of acne vulgaris. Molecules 2023, 28, 6395. [Google Scholar] [CrossRef]
- Eichenfield, D.Z.; Sprague, J.; Eichenfield, L.F. Management of acne vulgaris: A review. JAMA 2021, 326, 2055–2067. [Google Scholar] [CrossRef] [PubMed]
- Picardo, M.; Eichenfield, L.F.; Tan, J. Acne and rosacea. Dermatol. Ther. 2017, 7 (Suppl. 1), 43–52. [Google Scholar] [CrossRef] [PubMed]
- Agnew, T.; Leach, M.; Segal, L. The clinical impact and cost-effectiveness of essential oils and aromatherapy for the treatment of acne vulgaris: A protocol for a randomized controlled trial. J. Alternat. Complement. Med. 2014, 20, 399–405. [Google Scholar] [CrossRef]
- Chovatiya, R. Atopic dermatitis (eczema). JAMA 2023, 329, 268. [Google Scholar] [CrossRef]
- Clark, G.W.; Pope, S.M.; Jaboori, K.A. Diagnosis and treatment of seborrheic dermatitis. Am. Fam. Physician 2015, 91, 185–190. [Google Scholar] [PubMed]
- Naldi, L.; Diphoorn, J. Seborrhoeic dermatitis of the scalp. BMJ Clin. Evid. 2015, 2015, 1713. [Google Scholar] [PubMed] [PubMed Central]
- Jirabundansuk, P.; Ophaswongse, S.; Udompataikul, M. Comparative trial of moisturizer containing spent grain wax, Butyrospermum parkii extract, Argania spinosa kernel oil vs. 1% hydrocortisone cream in the treatment of childhood atopic dermatitis. J. Med. Assoc. Thai. 2014, 97, 820–826. [Google Scholar] [PubMed]
- Shortt, N.; Martin, A.; Kerse, K.; Shortt, G.; Vakalalabure, I.; Barker, L.; Singer, J.; Black, B.; Liu, A.; Eathorne, A.; et al. Efficacy of a 3% kānuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial. EClinicalMedicine 2022, 51, 101561. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA 2020, 323, 1945–1960. [Google Scholar] [CrossRef]
- Reich, K. Approach to managing patients with nail psoriasis. J. Eur. Acad. Dermatol. Venereol. 2009, 23 (Suppl. 1), 15–21. [Google Scholar] [CrossRef]
- Griffiths, C.E.M.; Armstrong, A.W.; Gudjonsson, J.E.; Barker, J. Psoriasis. Lancet 2021, 397, 1301–1315. [Google Scholar] [CrossRef]
- Lee, H.J.; Kim, M. Challenges and future trends in the treatment of psoriasis. Int. J. Mol. Sci. 2023, 24, 13313. [Google Scholar] [CrossRef]
- Two, A.M.; Wu, W.; Gallo, R.L.; Hata, T.R. Rosacea: Part I. Introduction, categorization, histology, pathogenesis, and risk factors. J. Am. Acad. Dermatol. 2015, 72, 749–758. [Google Scholar] [CrossRef]
- Van Zuuren, E.J.; Arents, B.W.M.; Van der Linden, M.M.D.; Vermeulen, S.; Fedorowicz, Z.; Tan, J. Rosacea: New concepts in classification and treatment. Am. J. Clin. Dermatol. 2021, 22, 457–465. [Google Scholar] [CrossRef]
- Searle, T.; Al-Niaimi, F.; Ali, F.R. Rosacea. Br. J. Hosp. Med. 2021, 82, 1–8. [Google Scholar] [CrossRef]
- Ahn, C.S.; Huang, W.W. Rosacea pathogenesis. Dermatol. Clin. 2018, 36, 81–86. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Ren, S.; Yang, H.; Tang, S.; Guo, C.; Liu, M.; Tao, Q.; Ming, T.; Xu, H. Peppermint essential oil: Its phytochemistry, biological activity, pharmacological effect and application. Biomed. Pharmacother. 2022, 154, 113559. [Google Scholar] [CrossRef] [PubMed]
- Rai, V.K.; Sinha, P.; Yadav, K.S.; Shukla, A.; Saxena, A.; Bawankule, D.U.; Tandon, S.; Khan, F.; Chanotiya, C.S.; Yadav, N.P. Anti-psoriatic effect of Lavandula angustifolia essential oil and its major components linalool and linalyl acetate. J. Ethnopharmacol. 2020, 261, 113127. [Google Scholar] [CrossRef] [PubMed]
- Kolahdooz, S.; Karimi, M.; Esmaili, N.; Zargaran, A.; Kordafshari, G.; Mozafari, N.; Hossein Ayati, M. Evaluation of the efficacy of a topical chamomile-pumpkin oleogel for the treatment of plaque psoriasis: An intra-patient, double-blind, randomized clinical trial. Biomed. Res. Ther. 2018, 5, 2811–2819. [Google Scholar] [CrossRef]
- Lin, Y.K.; See, L.C.; Huang, Y.H.; Chang, Y.C.; Tsou, T.C.; Lin, T.Y.; Lin, N.L. Efficacy and safety of indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: A randomized, observer-blind, vehicle-controlled trial. Phytomedicine 2014, 21, 1015–1020. [Google Scholar] [CrossRef]
- Fadaei, F.; Ayati, M.H.; Firooz, A.; Younespour, S.; Abouali, M.; Tabarrai, M.; Shirbeigi, L. Efficacy of a topical herbal cream containing frankincense oil, pumpkin oil and licorice aqueous extract in patients with mild-to-moderate plaque psoriasis: A randomized clinical trial. Res. J. Pharmacogn 2022, 9, 89–101. [Google Scholar] [CrossRef]
- Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015, 350, g7647. [Google Scholar] [CrossRef] [PubMed]
- ISO 4730:2017; Essential oil of Melaleuca, Terpinen-4-ol Type (Tea Tree Oil). International Organization for Standardization (ISO): Geneva, Switzerland, 2017.
- Enshaieh, S.; Jooya, A.; Siadat, A.H.; Iraji, F. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: A randomized, double-blind placebo-controlled study. Ind. J. Dermatol Venereol. Leprol. 2007, 73, 22–25. [Google Scholar] [CrossRef] [PubMed]
- Kwon, H.H.; Yoon, J.Y.; Park, S.Y.; Min, S.; Suh, D.H. Comparison of clinical and histological effects between lactobacillus-fermented Chamaecyparis obtusa and tea tree oil for the treatment of acne: An eight-week double-blind randomized controlled split-face study. Dermatology 2014, 229, 102–109. [Google Scholar] [CrossRef]
- Da Silva, A.G.; Puziol Pde, F.; Leitao, R.N.; Gomes, T.R.; Scherer, R.; Martins, M.L.; Cavalcanti, A.S.; Cavalcanti, L.C. Application of the essential oil from copaiba (Copaifera langsdori Desf.) for acne vulgaris: A double-blind, placebo-controlled clinical trial. Altern. Med. Rev. 2012, 17, 69–75. [Google Scholar] [PubMed]
- Bassett, I.B.; Pannowitz, D.L.; Barnetson, R.S. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med. J. Australia 1990, 153, 455–458. [Google Scholar] [CrossRef] [PubMed]
- Ghovvati, M.; Afshari, G.K.; Nasrollahi, S.A.; Firooz, A.; Samadi, A.; Karimi, M.; Talebi, Z.; Kolahdooz, S.; Vazirian, M. Efficacy of topical cinnamon gel for the treatment of facial acne vulgaris: A preliminary study. Biomed. Res. Ther. 2019, 6, 2958–2965. [Google Scholar] [CrossRef]
- Talebi, Z.; Afshari, G.K.; Nasrollahi, S.A.; Firooz, A.; Ghovvati, M.; Samadi, A.; Karimi, M.; Kolahdooz, S.; Vazirian, M. Potential of Trachyspermum ammi (Ajwain) gel for treatment of facial acne vulgaris: A pilot study with skin biophysical profile assessment and red fluorescence photography. Res. J. Pharmacogn. 2020, 7, 61–69. [Google Scholar] [CrossRef]
- Malhi, H.K.; Tu, J.; Riley, T.V.; Kumarasinghe, S.P.; Hammer, K.A. Tea tree oil gel for mild to moderate acne; a 12 week uncontrolled, open-label phase II pilot study. Australas. J. Dermatol. 2017, 58, 205–210. [Google Scholar] [CrossRef] [PubMed]
- Hassan, K.A.M.; Eltayb, N. Eucalyptus oil as a treatment for acne. Pharmanest 2013, 4, 557–566. [Google Scholar]
- Najafi-Taher, R.; Jafarzadeh Kohneloo, A.; Eslami Farsani, V.; Mehdizade Rayeni, N.; Moghimi, H.R.; Ehsani, A.; Amani, A. A topical gel of tea tree oil nanoemulsion containing adapalene versus adapalene marketed gel in patients with acne vulgaris: A randomized clinical trial. Arch. Dermatol. Res. 2022, 314, 673–679. [Google Scholar] [CrossRef] [PubMed]
- Najafi-Taher, R.; Ghaemi, B.; Amani, A. Delivery of adapalene using a novel topical gel based on tea tree oil nano-emulsion: Permeation, antibacterial and safety assessments. Eur. J. Pharm. Sci. 2018, 120, 142–151. [Google Scholar] [CrossRef] [PubMed]
- Mazzarello, V.; Donadu, M.G.; Ferrari, M.; Piga, G.; Usai, D.; Zanetti, S.; Sotgiu, M.A. Treatment of acne with a combination of propolis, tea tree oil, and Aloe vera compared to erythromycin cream: Two double-blind investigations. Clin. Pharmacol. 2018, 10, 175–181. [Google Scholar] [CrossRef] [PubMed]
- Mazzarello, V.; Gavini, E.; Rassu, G.; Donadu, M.G.; Usai, D.; Piu, G.; Pomponi, V.; Sucato, F.; Zanetti, S.; Montesu, M.A. Clinical assessment of new topical cream containing two essential oils combined with tretinoin in the treatment of acne. Clin. Cosmet. Investigat. Dermatol. 2020, 13, 233–239. [Google Scholar] [CrossRef] [PubMed]
- Parveen, S.; Zafar, S.; Qureshi, M.; Bano, H. Clinical trial of Unani herbomineral cream to evaluate its topical effects on acne vulgaris. Ind. J. Tradit. Knowl. 2009, 8, 431–436. [Google Scholar]
- Kim, B.Y.; Shin, B.S. Antimicrobial and improvement effects of tea tree and lavender oils on acne lesions. J. Converg. Informat. Technol. 2013, 8, 339–345. [Google Scholar]
- Orafidiya, L.O.; Agbani, E.O.; Oyedele, A.O.; Babalola, O.O.; Onayemi, O. Preliminary clinical tests on topical preparations of Ocimum gratissimum Linn leaf essential oil for the treatment of acne vulgaris. Clin. Drug Investig. 2002, 22, 313–319. [Google Scholar] [CrossRef]
- Orafidiya, L.O.; Agbani, E.O.; Oyedele, A.O.; Babalola, O.O.; Onayemi, O.; Aiyedun, F.F. The effect of aloe vera gel on the anti-acne properties of the essential oil of Ocimum gratissimum Linn leaf—A preliminary clinical investigation. Int. J. Aromather. 2004, 14, 15–21. [Google Scholar] [CrossRef]
- Hassoun, L.A.; Ornelas, J.N.; Sivamani, R.K. Cedarwood oil as complementary treatment in refractory acne. J. Alternat. Complement. Med. 2016, 22, 252–253. [Google Scholar] [CrossRef] [PubMed]
- Beheshti Roy, A.; Tavakoli-Far, B.; Fallah Huseini, H.; Tousi, P.; Shafigh, N.; Rahimzadeh, M. Efficacy of Melaleuca alternifolia essential oil in the treatment of facial seborrheic dermatitis: A double-blind, randomized, placebo-controlled clinical trial. J. Med. Plants 2014, 13, 26–32. [Google Scholar]
- De Valois, B. Using essential oils to treat scalp eczema. Int. J.Aromather. 2004, 14, 45–47. [Google Scholar] [CrossRef]
- Allan, R. Seborrhoeic dermatitis. Int. J. Aromather. 2003, 13, 47–48. [Google Scholar] [CrossRef]
- Thomas, J.; Narkowicz, C.K.; Jacobson, G.A.; Peterson, G.M. Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: A randomized, controlled trial. J. Clin. Pharm. Ther. 2015, 40, 566–572. [Google Scholar] [CrossRef] [PubMed]
- Hercogova, J.; Fioranelli, M.; Gianfaldoni, S.; Chokoeva, A.A.; Tchernev, G.; Wollina, U.; Tirant, M.; Novotny, F.; Roccia, M.G.; Maximov, G.K.; et al. Dr Michaels® (Soratinex®) product for the topical treatment of psoriasis: A Hungarian/Czech and Slovak study. J. Biol. Reg. Homeostat. Agents 2016, 30, 43–47. [Google Scholar]
- Fioranelli, M.; Gianfaldoni, H.J.S.; Chokoeva, A.; Tchernev, G.; Wollina, U.; Tirant, M.; Novotni, F.; Roccia, M.G.; Maximov, G.K.; França, K. Clinical evaluation of the effectiveness of Dr Michaels® (also branded as Soratinex®) products in the topical treatment of patients with plaque psoriasis. J Biol. Reg. Homeostat. Agents 2016, 30, 29–34. [Google Scholar]
- Ebneyamin, E.; Mansouri, P.; Rajabi, M.; Qomi, M.; Asgharian, R.; Azizian, Z. The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: A double-blind, controlled clinical trial. J. Cosmet. Dermatol. 2019, 19, 1426–1431. [Google Scholar] [CrossRef]
- Nascimento, T.; Gomes, D.; Simoes, R.; Maria Da Graca, M. Tea tree oil: Properties and the therapeutic approach to acne—A review. Antioxidants 2023, 12, 1264. [Google Scholar] [CrossRef]
- Howick, J.; Hoffmann, T. How placebo characteristics can influence estimates of intervention effects in trials. CMAJ 2018, 190, E908–E911. [Google Scholar] [CrossRef]
- Barrett, J.E.; Page, C.P.; Michel, M.C. Concepts and Principles of Pharmacology—100 Years of the Handbook of Experimental Pharmacology; Springer Nature: Cham, Switzerland, 2019. [Google Scholar]
- Togni, S.; Maramaldi, G.; Di Pierro, F.; Biondi, M. A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis. Clin. Cosmet. Investigat. Dermatol. 2014, 7, 321–327. [Google Scholar] [CrossRef]
- Nair, B. Clinical trial designs. Ind. Dermatol. Online J. 2019, 10, 193–201. [Google Scholar] [CrossRef]
- Arnold, B.F.; Ercumen, A. Negative control outcomes: A tool to detect bias in randomized trials. JAMA 2016, 316, 2597–2598. [Google Scholar] [CrossRef]
- Sticher, O.; Heilmann, J.; Zündorf, I. Hänsel/Sticher Pharmakognosie Phytopharmazie, 10th ed.; Wissenschaftliche Verlagsgesellschaft: Stuttgart, Germany, 2015. [Google Scholar]
- European Medicines Agency (EMA). Community Herbal Monograph on Eucalyptus Globulus Labill., Eucalyptus Polybractea R.T. Baker and/or Eucalyptus Smithii R.T. Baker, Aetheroleum; EMA: Amsterdam, The Netherlands, 2014; Available online: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eucalyptus-globulus-labill-eucalyptus-polybractea-rt-baker-andor-eucalyptus-smithii-rt-baker-aetheroleum_en.pdf (accessed on 28 March 2024).
- Bekhof, A.S.M.W.; Van Hunsel, F.P.A.M.; Van de Koppel, S.; Woerdenbag, H.J. Safety assessment and adverse drug reaction reporting of tea tree oil (Melaleuca aetheroleum). Phytother. Res. 2023, 37, 1309–1318. [Google Scholar] [CrossRef]
- Evans, C.H.; Ildstad, S.T. Institute of Medicine (US) Committee on Strategies for Small-Number-Participant Clinical Research Trials; National Academies Press: Washington, DC, USA, 2001. [Google Scholar]
- Tse, T.; Fain, K.M.; Zarin, D.A. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. BMJ 2018, 361, k1452. [Google Scholar] [CrossRef]
- Van de Wetering, F.T.; Scholten, R.J.P.M.; Haring, T.; Clarke, M.; Hooft, L. Trial registration numbers are underreported in biomedical publications. PLoS ONE 2012, 7, e49599. [Google Scholar] [CrossRef]
- Saeedi, M. Effect of Lavander Essential Oil in Comparison with Tretinoin on Acne. Trial Registry Record 22 February 2018. Available online: https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT2014072110203N3 (accessed on 2 April 2024).
- Rashidipour, M. Compare the Effectiveness of Betamethasone and Lavender and Peppermint in Reducing the Severity of Symptoms in Patients with Eczema and Psoriasis. Trial Registry Record 17 August 2020. Available online: https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20100420003760N4 (accessed on 2 April 2024).
- Soltani, R. Evaluation of the Effectiveness of Berberis integerrima and Thyme Essential Oil in the Treatment of Acne. Trial Registry Record 29 November 2021. Available online: https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20150721023282N21 (accessed on 2 April 2024).
- The EndNote Team. EndNote, Version EndNote X9; Clarivate: Philadelphia, PA, USA, 2013. [Google Scholar]
Author(s) (Publication Year; Country) | Study Design (n) | Intervention (n) | Control (n) | Outcome Measure(s) | Study Duration (Evaluation Period) | Main Results | Limitations |
---|---|---|---|---|---|---|---|
Behehsti Roy et al. (2014; Iran) [53] | Randomized, vehicle-controlled, double-blind design (54) | 5% TTO 1 gel (27) | Vehicle gel (27) | —Severity of seborrheic dermatitis —Extent of itching, erythema, scaling, and greasy crusts score —Patient satisfaction —Monitoring ADRs 2 | 4 weeks (baseline; 2 and 4 weeks) | —After 4 weeks, a significant decrease in the values of all parameters in the intervention group was observed, but there was no change in the vehicle group —After 4 weeks of treatment, 91% of the intervention group revealed a total cure —No allergic irritation or inflammation was reported | —Lack of comparison with standard therapy —Small sample size —Short duration |
Shortt et al. (2022; New Zealand) [20] | Single-blind, parallel group, superiority, randomized controlled trial, in a community setting (80) | 3% kānuka oil in cream (41) | Vehicle cream (39) | —POEM 3 —PO-SCORAD 4 —DLQI 5 —TSQM 6 —Photographs of eczema lesions —Monitoring ADRs 2, compliance, and concomitant medication use | 6 weeks (baseline; 6 and 8 weeks) | —The mean POEM 3 showed a statistically significant improvement with a greater degree in the intervention group compared to the control group —More participants in the intervention group experienced a clinically significant improvement of their POEM 3 score compared to the control group —No statistical difference in the PO-SCORAD 4, DLQI 5, and TSQM 6 scores between groups was observed —22 ADRs 2 were reported by the intervention group compared to 15 in the control group (no serious ADRs 2) | —Odor of the intervention might lead to bias —Bias between pharmacists and dermatologists —Short duration |
De Valois (2004; United Kingdom) [54] | Case study (1) | EO 7 formulation (base shampoo and scalp soak) (1) | NA | NA | 7 months (baseline; 2, 3, and 7 months) | —At 2 months, the condition was improved considerably but had not disappeared —At 3 months, continued improvement was observed, but the condition was still lingering —At 7 months, the condition had completely disappeared | —Only one case —Retrospective study —Uncontrolled —Patient was non-adherent and was not applying the intervention as prescribed |
Allan (2003; unknown) [55] | Case study (1) | Drops of EO 7 mixture (base shampoo) and a 2% dilution of the EO 7 mixture (aqueous-based cream) (1) | NA | NA | Number of weeks (few days, number of weeks, and number of months) | —Within a few days, the problem had completely gone —After stopping treatment for a number of months, the scalp had remained clear, but within the first weeks a tiny amount of dermatitis would reappear on his face —By using the cream once a week on his face, the areas affected by dermatitis remained clear | —Only one case —Retrospective study —Uncontrolled |
Author(s) (Publication Year; Country) | Intervention (Origin) | Intervention: Self-Made or Purchased | Control | Control: Self-Made or Purchased | Analyses of the EO-Containing Product |
---|---|---|---|---|---|
Behehsti Roy et al. (2014; Iran) [53] | 5% TTO 1 gel (Melaleuca alternifolia) | Purchased from Dr. Jahangir’s Company | Vehicle gel | Purchased from Dr. Jahangir’s Company | Not conducted |
Shortt et al. (2022; New Zealand) [20] | 3% kānuka oil cream (Kunzea ericoides) | Purchased | Vehicle cream | Not mentioned | Not conducted |
De Valois (2004; United Kingdom) [54] | EO 2 formulation with base shampoo and scalp soak | Purchased | NA | NA | Not conducted |
Allan (2003; unknown) [55] | Drops of EO 2 mixture, base shampoo, and a 2% dilution of the EO 2 mixture with an aqueous-based cream origin | Patient mixed 2–3 mL base shampoo with four drops of the EO 2 mixture | NA | NA | Not conducted |
Author(s) (Publication Year; Country) | Study Design (n) | Intervention (n) | Control (n) | Outcome Measure(s) | Study Duration (Evaluation Period) | Main Results | Limitations |
---|---|---|---|---|---|---|---|
Thomas et al. (2015; Australia) [56] | Randomized, active-controlled, double-blind design (30) | 20% kānuka oil in ointment and/or scalp lotion (15) | The same as the test formulation, but without the kānuka oil component (15) | —PASI 1 —Pruritus (VAS 2 scoring) —Monitoring ADRs 3 | 8 weeks (baseline; 2, 4, and 8 weeks) | —Two individuals from the test group and three from the control group did not respond to the treatment —After 8 weeks, both treatments showed significant improvements and the PASI 1 and VAS 2 scores decreased equally in the test group and control group (no significant difference between the groups) —Individuals treated with the test scalp lotion displayed a statistically comparable improvement rate compared to the control scalp lotion —No serious adverse events were reported; only 4 out of 26 individuals that used the scalp lotion reported itchiness in the beginning of the treatment | —Short-term follow-up —Control medication containing coal tar and salicylic acid —Short duration of the study |
Fadaei et al. (2021; Iran) [33] | Randomized, triple-blind, vehicle-controlled, parallel group study (108) | Frankincense oil (plus other constituents) in cream (45) | Vehicle cream (54) | —Photos of skin lesions —Compliance —PASI 1 —PGA 4 —BSA 5 —DLQI 6 —Pruritus severity scale —Patient satisfaction —Monitoring ADRs 3 | 4 weeks (baseline; 2 and 4 weeks) | —After 4 weeks of intervention, 53.19% of the patients in the intervention group and 2.44% in the vehicle group achieved a PASI 1 of 50% —Mean DLQI 6, PGA 4, and pruritus scores decreased in both groups over time —Mean BSA 5 score decreased significantly over time in the intervention group but not significantly in the vehicle group —After 4 weeks of intervention, the median patient satisfaction score was significantly higher in the intervention group compared to the vehicle group —2 patients reported skin reactions 24 h after exposure to the intervention | —Lack of comparison with a current topical treatment —Short duration of study and follow-up time |
Kohladooz et al. (2018; Iran) [31] | Randomized, intra-patient, double-blind, placebo-controlled clinical trial (40) | Chamomile-pumpkin (ChP) in oleogel (40) | Vehicle (40; liquid paraffin) | —Erythema, scaling, and induration severity scores —PSI 7 —PGA 4 —Photographs of the lesions —Patient satisfaction —Monitoring ADRs 3 | 4 weeks (baseline and 4 weeks) | —After 4 weeks, the PSI 7 score decline was significantly greater in the intervention group compared to the placebo group —After 4 weeks, the PGA 4 and overall patient satisfaction scores showed a significantly greater improvement in the intervention group compared to the placebo group —3 patients reported itching and irritation, which was more severe in the intervention group | —Lack of comparison with a current topical treatment —Risk of cross-contamination —Short duration of study and follow-up time —Small sample size |
Hercegova et al. (2016; Italy) [57] | Non-controlled pilot study (251) | Soratinex® scalp and body cleansing gel; scalp and body ointment and skin conditioner (251) | NA | —PASI 1 —Photography analysis —Monitoring ADRs 3 | 8 weeks (2 weeks before treatment; baseline; 1, 2, 4, 6, and 8 weeks) | —After 8 weeks, 13 individuals had no clinical improvements, 46 had a moderate improvement, 77 showed a good improvement, and 115 patients had an outstanding improvement —ADRs 3 were mild and temporary; however, 15 patients reported folliculitis and 7 patients reported contact dermatitis | —Lack of control group —Short duration of study and follow-up time —Small amount of outcome measures |
Fioranelli et al. (2016; Italy) [58] | Non-controlled pilot study (26) | Soratinex® scalp and body cleansing gel; scalp and body ointment and skin conditioner (26) | NA | —PASI 1 —Photography analysis —Monitoring ADRs 3 | 6 weeks (baseline; 1, 2, 3, 4, and 6 weeks (total time of observation was 8 weeks)) | —After 6 weeks, 3 individuals had no clinical improvements, 6 showed a slight improvement, 9 showed a good response, and 5 achieved an excellent improvement —7 patients reported mild and transient itching and 1 patient with scalp psoriasis discontinued treatment because of folliculitis-like inflammation | —Lack of control group —Small sample size —Short duration of study and follow-up time —Small amount of outcome measures |
Author(s) (Publication Year; Country) | Intervention (Origin) | Intervention: Self-Made or Purchased | Control | Control: Self-Made or Purchased | Analyses of the EO-containing Product |
---|---|---|---|---|---|
Thomas et al. (2015; Australia) [56] | 20% kānuka oil (from Kunzea ambigua) | Prepared in the compounding pharmaceutical laboratory of the School of Pharmacy at the University of Tasmania | The same as the test formulation, but without the kānuka oil component | Prepared in the compounding pharmaceutical laboratory of the School of Pharmacy at the University of Tasmania | Not conducted |
Fadaei et al. (2021; Iran) [33] | Boswellia spp. (the EO of frankincense and an ethanolic extract, the pulp of Cucurbita pepo, the and roots of Glycyrrhiza glabra) | Self-made (active products purchased from a local market in Teheran) | Vehicle cream | Self-made | —Organoleptic characteristics —Determination of pH —Mechanical stability —Temperature cycle test —Determination of viscosity —Microbial test —Total phenolic contents |
Kohladooz et al. (2018; Iran) [31] | Chamomile-pumpkin (ChP) oleogel (Matricaria chamomilla and Cucurbita pepo seed) | Self-extracted and self-made (standard pumpkin seed oil was purchased from the Giah Essence Phytopharm Co.) | Vehicle (liquid paraffin) | Self-made | Not conducted |
Hercegova et al. (2016; Italy) [57] | Soratinex® scalp and body cleansing gel; scalp and body ointment and skin conditioner | Purchased | NA | NA | Not conducted |
Fioranelli et al. (2016; Italy) [58] | Soratinex® scalp and body cleansing gel; scalp and body ointment and skin conditioner | Purchased | NA | NA | Not conducted |
Author(s) (Publication Year; Country) | Study Design (n) | Intervention (n) | Control (n) | Outcome Measure(s) | Study Duration (Evaluation Period) | Main Results | Limitations |
---|---|---|---|---|---|---|---|
Ebneyamin et al. (2019; Iran) [59] | Randomized, double-blind, placebo-controlled, prospective clinical trial (35) | 2.5% TTO 1 in permethrin gel (35) | Vehicle gel (35) | —SSSB 2 (mean Dd/cm2 3) —Erythema, papule and pustules, flushing, telangiectasia, edema, plaque, and stinging were monitored via photographs —Monitoring ADRs 4 | 12 weeks (baseline; 2, 5, 8, and 12 weeks) | —After 12 weeks, the mean Dd/cm2 3 on the treatment side were significantly decreased compared to the placebo side —After 12 weeks, a significant improvement in the papules and pustules, burning, stinging, and dry appearance were observed on the treatment side and not on the placebo side —Plaques, telangiectasia, flushing, and edema did not change on both sides —Mild-to-moderate ADRs 4 were reported by most of the individuals on both sides of their face with skin dryness, erosion, burning, and stinging being prevalent | —Risk of cross-contamination —No demographics reported —Small sample size —No distinction between the effect of permethrin and TTO 1 |
Author(s) (Publication Year; Country) | Intervention (Origin) | Intervention: Self-Made or Purchased | Control | Control: Self-Made or Purchased | Analyses of the EO-Containing Product |
---|---|---|---|---|---|
Ebneyamin et al. (2019; Iran) [59] | 2.5% permethrin with TTO 1 gel (Melaleuca alternifolia) | Not mentioned | Vehicle gel | Not mentioned | Not conducted |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dontje, A.E.W.K.; Schuiling-Veninga, C.C.M.; van Hunsel, F.P.A.M.; Ekhart, C.; Demirci, F.; Woerdenbag, H.J. The Therapeutic Potential of Essential Oils in Managing Inflammatory Skin Conditions: A Scoping Review. Pharmaceuticals 2024, 17, 571. https://doi.org/10.3390/ph17050571
Dontje AEWK, Schuiling-Veninga CCM, van Hunsel FPAM, Ekhart C, Demirci F, Woerdenbag HJ. The Therapeutic Potential of Essential Oils in Managing Inflammatory Skin Conditions: A Scoping Review. Pharmaceuticals. 2024; 17(5):571. https://doi.org/10.3390/ph17050571
Chicago/Turabian StyleDontje, Anouk E. W. K., Catharina C. M. Schuiling-Veninga, Florence P. A. M. van Hunsel, Corine Ekhart, Fatih Demirci, and Herman J. Woerdenbag. 2024. "The Therapeutic Potential of Essential Oils in Managing Inflammatory Skin Conditions: A Scoping Review" Pharmaceuticals 17, no. 5: 571. https://doi.org/10.3390/ph17050571
APA StyleDontje, A. E. W. K., Schuiling-Veninga, C. C. M., van Hunsel, F. P. A. M., Ekhart, C., Demirci, F., & Woerdenbag, H. J. (2024). The Therapeutic Potential of Essential Oils in Managing Inflammatory Skin Conditions: A Scoping Review. Pharmaceuticals, 17(5), 571. https://doi.org/10.3390/ph17050571